Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 3/23/2011 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Shawn Scranton?

Shawn A. Scranton

Senior Manager of Medical Research

Dura Pharmaceuticals , Inc.

HQ Phone:  (619) 457-2553

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Dura Pharmaceuticals , Inc.

7475 Lusk Boulevard

San Diego, California,92121

United States

Company Description

Dura Pharmaceuticals is a San Diego-based developer and marketer of prescription pharmaceutical products for the treatment of allergies, asthma and related respiratory conditions, and is developing a pulmonary drug delivery system. Dura's mission is to be the ...more

Background Information

Employment History

Vice President of Scientific Operations

Pharmacy Choice Inc


Director of Clinical Research

Uros , Ltd.


Program Director of the Program

SDX101


Vice President

Victory Pharma , Inc.


Principal Investigator On Industry

Baylor College of Medicine


Director of Clinical Development and Program Director of the SDX101 Program

Salmedix , Inc.


Senior Director of Translational Medicine

Kalypsys , Inc.


Assistant Professor

College of Pharmacy


Senior Director

Translational


Academic Positions

University of the Pacific


Web References(11 Total References)


Victory Pharma - Management Team

www.victorypharma.com [cached]

Shawn A. Scranton, Pharm.
D., Vice President of Scientific Operations Dr. Scranton brings more than 19 years of clinical development experience to Victory. Most recently, he was Senior Director of Translational Medicine for Kalypsys, Inc., where he contributed to non-clinical, regulatory, and clinical strategies that enabled the successful opening of NCE INDs, and conducting Phase 1 clinical programs in neuropathic pain and metabolic disease. Formerly, Dr. Scranton was Director of Clinical Development and program director of the SDX-101 program for Salmedix, Inc., which was acquired by Cephalon. He began his commercial career as a Senior Clinical Research Scientist at Dura Pharmaceuticals after holding a series of academic positions at Baylor College of Medicine, where he served as a Principal Investigator on a number of industry and government-supported clinical trials. Dr. Scranton earned his Pharm.D. from the University of the Pacific School of Pharmacy, where he also completed a fellowship in cardiovascular pharmacology. He earned his B.A. in Animal Physiology from University of California, San Diego.


Situs Corporation - Press Release : 04/27/00

www.situscorp.com [cached]

Situs Corporation names Shawn Scranton director of Clinical ResearchSitus Corporation - Press Release : 04/27/00This is the Situs Corporation's LogoImportant Notice Home Executive Summary Markets SITUS CORPORATION NAMES SHAWN SCRANTON DIRECTOR OF CLINICAL RESEARCH Situs Corporation names Shawn Scranton director of Clinical Research SAN DIEGO, CA – January 24, 2001 – Situs Corporation, developer of a novel drug delivery platform for the administration of intravesical (bladder) drugs, today announced the appointment of Shawn A. Scranton Pharm.D. as Director of Clinical Research.Dr. Scranton brings to Situs experience in the pharmaceutical and clinical pharmacotherapy industries, according to Tate Scott, President and CEO of Situs. Most recently Dr. Scranton served as Senior Manager of Medical Research at Dura Pharmaceuticals.During his tenure at Dura he was responsible for study design, scientific conduct, and data analysis of numerous Phase I – IV clinical trials.Prior to that, he was an Assistant Professor at the University of Houston, College of Pharmacy and conducted clinical research in the area of cardiovascular pharmacodynamics.Dr. Scranton received his Doctor of Pharmacy from the University of the Pacific School of Pharmacy, where he later completed a post-doctoral fellowship in cardiovascular pharmacotherapy.He also completed a clinical pharmacy residency at Veterans Affairs Medical Center in San Diego and worked as a Clinical Pharmacist at several leading hospitals in Houston and San Diego. Situs is a combination specialty pharmaceutical and drug delivery device manufacturer pioneering an intravesical drug delivery platform.The Company's proprietary UROS Infusor is one of the most unique methods of drug delivery and provides a solution for the inadequacies of conventional therapies.In addition to the treatment of overactive bladder, other applications include chemotherapeutic agents for bladder cancer, hormones for genitourinary conditions and analgesics for pain.The Company is headquartered in Solana Beach, California. This press release contains forward-looking statements, such as projecting future performance of products and materials, which include some risk and uncertainty.


Situs Corporation - Press Release : 04/27/00

www.uros.com [cached]

Situs Corporation names Shawn Scranton director of Clinical ResearchSitus Corporation - Press_Release : 04/27/00This is the Situs Corporation's Logo.Situs Corporation names Shawn Scranton director of Clinical Research.SAN_DIEGO , CA – January 24 , 2001 , DATE : [ 01/24/2001 ]Situs Corporation , developer of a novel drug delivery platform for the administration of intravesical ( bladder ) drugs , today announced the appointment of Shawn A. Scranton Pharm.D. as Director of Clinical Research.Dr. Scranton brings to Situs experience in the pharmaceutical and clinical pharmacotherapy industries , according to Tate Scott , President and CEO of Situs.Most recently Dr. Scranton served as Senior_Manager of Medical Research at Dura Pharmaceuticals.During his tenure at Dura he was responsible for study design , scientific conduct , and data analysis of numerous Phase I – IV clinical trials.Prior_to that , he was an Assistant Professor at the University of Houston , College of Pharmacy and conducted clinical research in the area of cardiovascular pharmacodynamics.Dr. Scranton received his Doctor of Pharmacy from the University of the Pacific School of Pharmacy , where he later completed a post-doctoral fellowship in cardiovascular pharmacotherapy.He also completed a clinical pharmacy residency at Veterans Affairs Medical Center in San_Diego and worked as a Clinical Pharmacist at several leading hospitals in Houston and San_Diego.Situs is a combination specialty pharmaceutical and drug delivery device manufacturer pioneering an intravesical drug delivery platform.The Company's proprietary UROS Infusor is one of the most unique methods of drug delivery and provides a solution for the inadequacies of conventional therapies.In_addition to the treatment of overactive bladder , other applications include chemotherapeutic agents for bladder cancer , hormones for genitourinary conditions and analgesics for pain.The Company is headquartered in Solana_Beach , California.This press_release contains forward-looking statements , such_as projecting future performance of products and materials , which include some risk and uncertainty.


Matt Heck Email Victory Pharma CEO CFO VP @victorypharma.com

www.lead411.com [cached]

Shawn Scranton
VP Scientific Operations


www.pharmpro.com

"We believe the attributes of MGX006 will provide an important alternative for patients suffering from nausea and vomiting of various etiologies," said Dr. Shawn Scranton, Vice President, Scientific Operations.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory